PMID- 37818076
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231031
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 13
IP  - 9
DP  - 2023
TI  - Investigating novel biomarkers in uterine corpus endometrial carcinoma: in silico 
      analysis and clinical specimens validation via RT-qPCR and immunohistochemistry.
PG  - 4376-4400
AB  - The rising incidence and mortality rate of Uterine Corpus Endometrial Carcinoma 
      (UCEC) pose significant health concerns. CC and CXC chemokines have been linked 
      to tumorigenesis and cancer progression. Recognizing the growing significance of 
      CC and CXC chemokines' diagnostic and prognostic significance in diverse cancer 
      types, our objective was to comprehensively analyze the diagnostic and prognostic 
      values of hub genes from the CC and CXC chemokines in UCEC, utilizing both in 
      silico and clinical samples and cell lines-based approaches. In silico analyses 
      include STRING, Cytoscape, Cytohubba, The Cancer Genome Atlas (TCGA) datasets 
      analysis via the UALCAN, GEPIA, OncoDB, and MuTarget, SurvivalGenie, MEXPRESS, 
      cBioPoratal, TIMER, ENCORI, and DrugBank. Meanwhile, clinical samples and cell 
      lines based analyses include Reverse transcription-quantitative polymerase chain 
      reaction (RT-qPCR), targeted bisulfite sequencing (bisulfite-seq) analysis, and 
      immunohistochemistry (IHC). Through present study, we identified CCL25 (CC motif 
      chemokine ligand 25), CXCL10 (C-X-C motif chemokine ligand 10), CXCL12 (C-X-C 
      motif chemokine ligand 12), and CXCL16 (C-X-C motif chemokine ligand 16) as 
      crucial hub genes among the CC and CXC chemokines. Analyzing the expression data 
      from TCGA, we observed a significant up-regulation of CCL25, CXCL10, and CXCL16 
      in UCEC samples compared to controls. In contrast, we noted a significant 
      down-regulation of CXCL12 expression in UCEC samples. On clinical UCEC samples 
      and cell lines analysis, the significant higher expression of CCL25, CXCL10, and 
      CXCL16 and significant lower expression of CXCL12 were also denoted in UCEC 
      samples than the controls via RT-qPCR and IHC analyses. Moreover, in silico 
      analysis also confirmed the abnormal promoter methylation levels of the hub genes 
      in TCGA UCEC samples, which was later validated by the clinical samples using 
      targeted based bisulfite-seq analysis. In addition, various additional aspects of 
      the CCL25, CXCL10, CXCL12, and CXCL16 have also been uncovered in UCEC during the 
      present study. Our findings offer novel insights that contribute to the clinical 
      utility of CCL25, CXCL10, CXCL12, and CXCL16 chemokines as potential diagnostic 
      and prognostic biomarkers in UCEC.
CI  - AJCR Copyright (c) 2023.
FAU - Li, Jie
AU  - Li J
AD  - Health Management Center, The Second Affiliated Hospital of Hainan Medical 
      University Haikou 570311, Hainan, China.
FAU - Ramzan, Faiqah
AU  - Ramzan F
AD  - Gomal Center of Bio-Chemistry and Biotechnology (GCBB), Gomal University Dera 
      Ismail Khan 29050, Pakistan.
FAU - Zhong, Guiping
AU  - Zhong G
AD  - Health Management Center, The Second Affiliated Hospital of Hainan Medical 
      University Haikou 570311, Hainan, China.
LA  - eng
PT  - Journal Article
DEP - 20230915
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC10560950
OTO - NOTNLM
OT  - CC and CXC chemokines
OT  - UCEC
OT  - biomarkers
COIS- None.
EDAT- 2023/10/11 06:45
MHDA- 2023/10/11 06:46
PMCR- 2023/09/15
CRDT- 2023/10/11 03:50
PHST- 2023/06/08 00:00 [received]
PHST- 2023/08/17 00:00 [accepted]
PHST- 2023/10/11 06:46 [medline]
PHST- 2023/10/11 06:45 [pubmed]
PHST- 2023/10/11 03:50 [entrez]
PHST- 2023/09/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2023 Sep 15;13(9):4376-4400. eCollection 2023.